Browsing by Author "Madoz-Gúrpide, Juan"

Sort by: Order: Results:

  • Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
    Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico (e-Century Publishing, 2017)
    Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to ...
  • PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
    Rincón, Raúl; Cristóbal, Ion; Zazo, Sandra; Arpí Llucià, Oriol; Menendez Romero, Silvia; Manso, Rebeca; Lluch, Ana; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; García-Foncillas, Jesús; Madoz-Gúrpide, Juan; Rojo, Federico (Impact Journals, 2015)
    The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A ...
  • The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
    Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Research, 2019)
    The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of ...